

FAX TRANSMISSION

DATE: October 30, 2003

PTO IDENTIFIER: Application Number 09/832,129-Conf. #1593
Patent Number

Inventor: Fiscella et al.

MESSAGE TO: H. Robinson

FAX NUMBER: 703-746-5128

FROM: HUMAN GENOME SCIENCES, INC.

Janet M. Martineau

PHONE: (301) 315-2723

Attorney Dkt. #: PZ045P1

PAGES (Including Cover Sheet): 4

CONTENTS: Fax Transmission;
Draft Amended Claims

If your receipt of this transmission is in error, please notify this firm immediately by collect call to sender at (301) 315-2723 and send the original transmission to us by return mail at the address below.

This transmission is intended for the sole use of the individual and entity to whom it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. You are hereby notified that any dissemination, distribution or duplication of this transmission by someone other than the intended addressee or its designated agent is strictly prohibited.

HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue, Rockville, Maryland 20850
Telephone: (301) 610-5790 Facsimile: (301) 309-8439

Examiner Robinson: As discussed today, claims 37 and 42 have been amended. Let me know if you need any more information. Thank you.

DRAFT AMENDMENT

Amendment to the Claims:

This listing of claims shall replace all prior versions and listing of claims in the application.

Listing of claims:

Claims 1-24 (canceled)

Claim 25 (previously added) An isolated protein comprising amino acid residues 34 to 766 of SEQ ID NO:35.

Claim 26 (previously added) The isolated protein of claim 25 which comprises amino acid residues 2 to 766 of SEQ ID NO:35.

Claim 27 (previously added) The isolated protein of claim 25 which comprises amino acid residues 1 to 766 of SEQ ID NO:35.

Claim 28 (previously added) The protein of claim 25 which further comprises a heterologous polypeptide sequence.

Claim 29 (previously added) A composition comprising the protein of claim 25 and a pharmaceutically acceptable carrier.

Claim 30 (previously added) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 25 by a cell; and
(b) recovering said protein.

Claim 31 (previously added) An isolated protein comprising the amino acid sequence of the secreted portion of the polypeptide encoded by the HCE3C63 cDNA contained in ATCC Deposit No. PTA-909.

Claim 32 (previously added) The isolated protein of claim 31 which comprises the amino acid sequence of the complete polypeptide encoded by the HCE3C63 cDNA contained in ATCC Deposit No. PTA-909, excepting the N-terminal methionine.

Claim 33 (previously added) The isolated protein of claim 31 which comprises the amino acid sequence of the complete polypeptide encoded by the HCE3C63 cDNA contained in ATCC Deposit No. PTA-909.

Claim 34 (previously added) The protein of claim 31 which further comprises a heterologous polypeptide sequence.

Claim 35 (previously added) A composition comprising the protein of claim 31 and a pharmaceutically acceptable carrier.

Claim 36 (previously added) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 31 by a cell; and
(b) recovering said protein.

Claim 37 (currently amended) An isolated protein comprising consisting of a polypeptide sequence which is at least 90% identical to amino acid residues 1 to 766 of SEQ ID NO:35, wherein said sequence generates an antibody that specifically binds to a polypeptide having an amino acid sequence consisting of amino acid residues 1 to 766 of SEQ ID NO:35.

Claim 38 (previously added) The isolated protein of claim 37, wherein said polypeptide sequence is at least 95% identical to amino acid residues 1 to 766 of SEQ ID NO:35.

Claim 39 (previously added) The protein of claim 37 which further comprises a heterologous polypeptide sequence.

Claim 40 (previously added) A composition comprising the protein of claim 37 and a pharmaceutically acceptable carrier.

Claim 41 (previously added) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 37 by a cell; and
(b) recovering said protein.

Claim 42 (currently amended) An isolated protein comprising consisting of a polypeptide sequence which is at least 90% identical to the complete polypeptide encoded by the HCE3C63 cDNA contained in ATCC Deposit No. PTA-909, wherein said sequence generates an antibody that specifically binds to the complete polypeptide encoded by the HCE3C63 cDNA contained in ATCC Deposit No. PTA-909.

Claim 43 (previously added) The isolated protein of claim 42, wherein said polypeptide sequence is at least 95% identical to the complete polypeptide encoded by the HCE3C63 cDNA contained in ATCC Deposit No. PTA-909.

Claim 44 (previously added) The protein of claim 42 which further comprises a heterologous polypeptide sequence.

Claim 45 (previously added) A composition comprising the protein of claim 42 and a pharmaceutically acceptable carrier.

Claim 46 (previously added) An isolated protein produced by the method comprising:
(a) expressing the protein of claim 42 by a cell; and
(b) recovering said protein.